Clinical Trial

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

Study acronym: SPARK
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-09-13; most recent amendment 2025-11-07.
Status change: Not Yet Recruiting → Recruiting 2025-04-01
Trial Details
NCT Number NCT06601296
Lead Sponsor University of Texas Southwestern Medical Center
Conditions Metastatic Renal Cell Carcinoma ( mRCC), OligoProgressive Metastatic Disease
Enrollment 15 participants
Start Date 2025-04-01
Primary Completion 2027-10 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-12